News Releases

Date Title and Summary View
March 3, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 3, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 5,000 shares of...
Additional Formats
February 28, 2022
– KVD900 Phase 2 data presented at the American Academy of Allergy , Asthma & Immunology (AAAAI) Annual Scientific Meeting – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 28, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...
Additional Formats
February 3, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 3, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a...
Additional Formats
February 2, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 2, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that new data on...
Additional Formats
February 2, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 2, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 19,000 shares of...
Additional Formats
January 24, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 24, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data from the Phase 1...
Additional Formats
January 4, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 4, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 23,000 shares of...
Additional Formats
Displaying 31 - 37 of 37